跳轉至內容
Merck
  • Simulation of drug distribution in the vitreous body after local drug application into intact vitreous body and in progress of posterior vitreous detachment.

Simulation of drug distribution in the vitreous body after local drug application into intact vitreous body and in progress of posterior vitreous detachment.

Journal of pharmaceutical sciences (2013-12-07)
Christian Loch, Malte Bogdahn, Sandra Stein, Stefan Nagel, Rudolf Guthoff, Werner Weitschies, Anne Seidlitz
摘要

Intravitreal injections and drug-loaded implants are current approaches to treat diseases of the posterior eye. To investigate the release of active agents and their distribution in the vitreous body, a new test system was developed that enables a realistic simulation of eye motions. It is called the eye movement system (EyeMoS). In combination with a previously developed model containing a polyacrylamide gel as a substitute for the vitreous body, this new system enables the characterization of the influence of eye motions on drug distribution within the vitreous body. In the presented work, the distribution of fluorescence-tagged model drugs of different molecular weight within the simulated vitreous was examined under movement with the EyeMoS and without movement. By replacing a part of the gel in the simulated vitreous body with buffer, the influence of the progress of posterior vitreous detachment (PVD) on the distribution of these model substances was also studied. The results indicate that convective forces may be of predominate influence on initial drug distribution. The impact of these forces on drug transport increases with simulated progression of PVD. Using the EyeMoS, the investigation of release and distribution from intravitreal drug delivery systems becomes feasible under biorelevant conditions.

材料
產品編號
品牌
產品描述

Sigma-Aldrich
甲醇, suitable for HPLC, ≥99.9%
Sigma-Aldrich
甲醇, ACS reagent, ≥99.8%
Sigma-Aldrich
甲醇, suitable for HPLC, gradient grade, ≥99.9%
Sigma-Aldrich
甲醇, HPLC Plus, ≥99.9%
Sigma-Aldrich
四甲基乙二胺, BioReagent, suitable for electrophoresis, ≥99.0%
Sigma-Aldrich
甲醇, puriss. p.a., ACS reagent, reag. ISO, reag. Ph. Eur., ≥99.8% (GC)
Sigma-Aldrich
甲醇, Laboratory Reagent, ≥99.6%
Sigma-Aldrich
甲醇, anhydrous, 99.8%
Sigma-Aldrich
四甲基乙二胺, BioReagent, for molecular biology, ≥99% (GC)
Sigma-Aldrich
甲醇, BioReagent, ≥99.93%
Sigma-Aldrich
甲醇, Absolute - Acetone free
Sigma-Aldrich
甲醇, ACS spectrophotometric grade, ≥99.9%
Sigma-Aldrich
四甲基乙二胺, ≥99.5%, purified by redistillation
Sigma-Aldrich
荧光素异硫氰酸酯异构体I, suitable for protein labeling, ≥90% (HPLC), powder
Sigma-Aldrich
荧光素 5(6)-异硫氰酸酯, BioReagent, suitable for fluorescence, mixture of 2 components, ≥90% (HPLC)
Sigma-Aldrich
甲醇, ACS reagent, ≥99.8%
USP
木精, United States Pharmacopeia (USP) Reference Standard
Supelco
甲醇, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
四甲基乙二胺, ReagentPlus®, 99%
Sigma-Aldrich
甲醇, ACS reagent, ≥99.8%
Supelco
甲醇, analytical standard
Sigma-Aldrich
荧光素 5(6)-异硫氰酸酯, ≥90% (HPLC)
Sigma-Aldrich
甲醇, puriss., meets analytical specification of Ph Eur, ≥99.7% (GC)
Sigma-Aldrich
荧光素异硫氰酸酯异构体I, ≥97.5% (HPLC)
Sigma-Aldrich
甲醇, NMR reference standard
Sigma-Aldrich
甲醇, HPLC Plus, ≥99.9%, poly-coated bottles
Sigma-Aldrich
甲醇-12C, 99.95 atom % 12C
Sigma-Aldrich
Anti-Human IgG (H+L)-Rhodamine antibody produced in goat, affinity isolated antibody, lyophilized powder